{
  "schemaVersion": 1,
  "id": "research-096",
  "slug": "096-why-the-dsip-withdrawal-reports-cannot-establish-a-treatment-effect",
  "title": "Why the DSIP Withdrawal Reports Cannot Establish a Treatment Effect",
  "catalogLabel": "DSIP",
  "productCollection": "https://heritagebiolabs.com/research-library/products/dsip",
  "productHandles": [
    "dsip-433"
  ],
  "productUrls": [
    "https://heritagebiolabs.com/product/dsip-433"
  ],
  "readingFocus": "Interpreting evidence",
  "readingFocusNote": "Reading focus is a navigational tag, not an evidence grade.",
  "wordCount": 298,
  "sourceYears": [
    1984,
    1998,
    2026
  ],
  "paragraphs": [
    "Peptides are short chains of amino acids linked by peptide bonds. Researchers sometimes test whether a chain influences several signals at once, but a change in symptoms can have more than one cause. Delta sleep-inducing peptide, also called emideltide, was studied in historical reports of substance withdrawal. The FDA reexamined this literature in 2026. The older reports are useful for understanding what investigators observed and which comparisons were missing. [1, 2, 3]",
    "One report included people hospitalized with withdrawal from alcohol or opioids. It recorded clinical signs and patients' accounts of symptoms after exposure to DSIP. Another published report, from 1998, was explicitly an open clinical trial. In an open study, participants and staff may know what was given. That leaves expectations, other care and the natural course of withdrawal as possible explanations for a change. The 2026 appraisal also noted that some participants in the older series had renewed anxiety and insomnia after treatment stopped. [1, 2, 3]",
    "The most important limitation is the missing counterfactual: what would have happened to comparable participants receiving the same support without the experimental peptide? Even accurate symptom observations cannot answer that by themselves. The reports also address a relatively short period of withdrawal. They cannot establish long-term outcomes such as recovery, sustained participation in care, relapse or overdose risk. An effect on sleep or physical discomfort in an observation period would not prove an effect on those outcomes. [1]",
    "The FDA did not conclude that the available data establish effectiveness for opioid withdrawal. This research history shows why small, uncontrolled studies can help formulate questions while leaving the central treatment comparison unresolved. A new controlled study would have to define which outcomes mattered, account for other care and follow participants long enough to observe more than immediate symptom fluctuation. [1]"
  ],
  "sources": [
    {
      "number": 1,
      "citation": "US Food and Drug Administration. FDA Briefing Document for Emideltide-Related Bulk Drug Substances. Pharmacy Compounding Advisory Committee (2026-07-23).",
      "url": "https://www.fda.gov/media/193344/download"
    },
    {
      "number": 2,
      "citation": "Dick P et al. DSIP in the treatment of withdrawal syndromes from alcohol and opiates. European Neurology (1984).",
      "url": "https://pubmed.ncbi.nlm.nih.gov/6548969/"
    },
    {
      "number": 3,
      "citation": "Backmund M et al. Opioid detoxification with delta sleep-inducing peptide: results of an open clinical trial. Journal of Substance Abuse Treatment (1998-06).",
      "url": "https://pubmed.ncbi.nlm.nih.gov/9617990/"
    }
  ],
  "canonicalUrl": "https://heritagebiolabs.com/research-library/articles/096-why-the-dsip-withdrawal-reports-cannot-establish-a-treatment-effect",
  "markdownUrl": "https://heritagebiolabs.com/research-library/data/articles/096-why-the-dsip-withdrawal-reports-cannot-establish-a-treatment-effect.md",
  "jsonUrl": "https://heritagebiolabs.com/research-library/data/articles/096-why-the-dsip-withdrawal-reports-cannot-establish-a-treatment-effect.json",
  "provenance": {
    "sourceArchive": "Peptide Research Articles - All 82 Volumes.zip",
    "sourceArchiveSha256": "9796bec477cbe2f8017dda81c7e58260985a13bdda1f934e8eb8d0549c2cada5",
    "sourceVolume": "Peptide Research Articles 020 - DSIP and Epitalon.docx",
    "sourceArticleNumber": 96,
    "contentSha256": "f3538146548f06d1c42c6ad978ea2d569f164fac315cdfc546c3419176990c54",
    "statement": "Article titles, body paragraphs and numbered citations extracted without rewriting from owner-supplied Word volumes. Product mappings use exact catalog labels; reading-focus tags and excerpts are navigational metadata. No independent peer-review or comprehensive source verification is claimed."
  },
  "scope": "Educational article about published research. For research use only; not medical advice. Literature does not establish the identity, purity or activity of a purchased lot, and studies of individual components do not validate a blend."
}
